Bain Capital Life Sciences Investors’s BCLS Acquisition Corp. Class A Ordinary Shares BLSA Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio BLSA Stock Details BLSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-487,500	Closed	-$4.88M	–	37
2022 Q3	$4.88M	Hold	487,500	–	–	0.58%	28
2022 Q2	$4.83M	Hold	487,500	–	–	0.57%	32
2022 Q1	$4.81M	Hold	487,500	–	–	0.47%	31
2021 Q4	$4.78M	Hold	487,500	–	–	0.38%	30
2021 Q3	$4.86M	Hold	487,500	–	–	0.3%	29
2021 Q2	$5.13M	Hold	487,500	–	–	0.34%	25
2021 Q1	$5.15M	Hold	487,500	–	–	0.29%	27
2020 Q4	$5.43M	Buy	+487,500	New	+$5.23M	0.34%	23

Bain Capital Life Sciences Investors's BLSA Position: Q4 2022 in Review

Bain Capital Life Sciences Investors sold out of BCLS Acquisition Corp. Class A Ordinary Shares (BLSA) in Q4 2022, closing a stake of 487,500 shares — an estimated $4.88M sold.

Bain Capital Life Sciences Investors first reported a position in BLSA in Q4 2020 and held it in 8 quarters. The position peaked at $5.43M in Q4 2020. 0 funds tracked by Wall St. Rank hold BLSA as of Q4 2022.

Bain Capital Life Sciences Investors reported no remaining BCLS Acquisition Corp. Class A Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Bain Capital Life Sciences Investors sold 487,500 BCLS Acquisition Corp. Class A Ordinary Shares shares in Q4 2022, an estimated $4.88M.
Bain Capital Life Sciences Investors first reported a position in BCLS Acquisition Corp. Class A Ordinary Shares in Q4 2020 and held it in 8 quarters.
Bain Capital Life Sciences Investors's BCLS Acquisition Corp. Class A Ordinary Shares position peaked at $5.43M in Q4 2020.
0 funds tracked by Wall St. Rank held BCLS Acquisition Corp. Class A Ordinary Shares as of Q4 2022.

Based on Bain Capital Life Sciences Investors's 13F filing for Q4 2022, filed 14 Feb 2023.